WANTAI BIOLOGICAL(SH:603392)2023-04-20 16:00Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,886,602,037.70, representing a decrease of 8.98% compared to the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was RMB 1,244,917,930.85, down 6.46% year-on-year[4]. - The diluted earnings per share for Q1 2023 was RMB 1.38, reflecting a decline of 8.61%[1]. - Total revenue for Q1 2023 was CNY 2,886,602,037.70, a decrease of 9.0% compared to CNY 3,171,223,475.09 in Q1 2022[20]. - Operating profit for Q1 2023 was CNY 1,433,596,712.00, down from CNY 1,631,731,632.61 in Q1 2022, reflecting a decline of 12.1%[21]. - Net profit for Q1 2023 was CNY 1,252,742,514.19, compared to CNY 1,386,767,882.04 in Q1 2022, representing a decrease of 9.7%[21]. - Basic earnings per share for Q1 2023 were CNY 1.38, down from CNY 1.51 in Q1 2022, a decrease of 8.6%[22]. Cash Flow and Investments - The net cash flow from operating activities was negative RMB 313,683,356.17, a significant decrease of 170.00% compared to the previous year[4]. - In Q1 2023, the cash inflow from operating activities was CNY 1,705,154,373.92, compared to CNY 1,678,729,660.33 in Q1 2022, reflecting a slight increase[23]. - The net cash flow from operating activities in Q1 2023 was CNY -313,683,356.17, a decrease from CNY 448,101,537.24 in Q1 2022[23]. - Cash inflow from investment activities totaled CNY 1,142,095,641.03 in Q1 2023, significantly up from CNY 12,499,574.70 in Q1 2022[24]. - The net cash flow from investment activities was CNY -481,231,342.96 in Q1 2023, worsening from CNY -296,359,100.14 in Q1 2022[24]. - Cash inflow from financing activities was CNY 25,519,500.00 in Q1 2023, down from CNY 120,000,000.00 in Q1 2022[24]. - The net cash flow from financing activities was CNY -23,898,209.58 in Q1 2023, compared to CNY 46,054,986.29 in Q1 2022[24]. - The company reported a significant increase in cash outflow for operating activities, totaling CNY 2,018,837,730.09 in Q1 2023, compared to CNY 1,230,628,123.09 in Q1 2022[23]. - The cash outflow for investment activities in Q1 2023 was CNY 1,623,326,983.99, compared to CNY 308,858,674.84 in Q1 2022, indicating increased investment spending[24]. - The company experienced a net decrease in cash and cash equivalents of CNY 821,899,852.16 in Q1 2023, contrasting with an increase of CNY 192,570,932.27 in Q1 2022[24]. Assets and Liabilities - Total assets at the end of Q1 2023 were RMB 17,253,876,518.46, an increase of 6.31% from the end of the previous year[6]. - Total assets as of March 31, 2023, amounted to CNY 17,253,876,518.46, an increase from CNY 16,229,516,571.12 at the end of 2022[18]. - Current assets totaled CNY 12,919,449,862.76 as of March 31, 2023, compared to CNY 12,179,759,105.13 at the end of 2022, indicating a growth of 6.1%[18]. - The company's cash and cash equivalents decreased to CNY 4,371,171,076.64 from CNY 5,192,247,920.74, a decline of 15.8%[18]. - Total liabilities decreased to CNY 3,476,242,147.29 from CNY 3,664,624,714.14, reflecting a reduction of 5.2%[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,142[11]. - The largest shareholder, Yangshengtang Co., Ltd., held 55.64% of the shares, totaling 504,148,520 shares[11]. Research and Development - The company incurred RMB 71 million in research and development expenses related to the nasal spray COVID-19 vaccine, which were fully expensed this quarter[6]. - Research and development expenses increased significantly to CNY 217,843,428.15 in Q1 2023, up from CNY 106,310,269.96 in Q1 2022, marking a rise of 104.0%[20]. Credit Impairment - The company reported a significant credit impairment loss of CNY -69,527,051.75 in Q1 2023, compared to CNY -82,611,533.09 in Q1 2022[20].